{"id":1009031,"date":"2026-10-09T16:45:46","date_gmt":"2026-10-09T20:45:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/"},"modified":"2026-10-09T16:45:46","modified_gmt":"2026-10-09T20:45:46","slug":"lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Oct.  09, 2026  (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Kozauer and Mr. Miller entering into employment with LB Pharmaceuticals.<\/p>\n<p align=\"justify\">Dr. Kozauer and Mr. Miller each received an option to purchase 200,000 shares of LB Pharmaceuticals\u2019 common stock. The options carry a ten-year term and an exercise price per share equal to $37.22, which was the closing price of LB Pharmaceuticals\u2019 common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1\/48th of the shares vesting monthly thereafter, subject to continuous service through the applicable vesting dates.<\/p>\n<p align=\"justify\">\n        <strong>About LB Pharmaceuticals<\/strong>\n      <\/p>\n<p align=\"justify\">LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.<\/p>\n<p align=\"justify\">\n        <strong>Media and Investor Contact<\/strong>:\u00a0<\/p>\n<p align=\"justify\">Ellen Rose<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hel0NrbNu7LNG4tzsm_YuS5xHHMrraavmGHRM9PWlC0KM_JZ8cqYZ-IwqGVd2swrL0EE60ZlaG4wyRfbwoujE-l6PgU4iERogYEH0uTd4DE=\" rel=\"nofollow\" target=\"_blank\">erose@lbpharma.us<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzI4MDg2OTgtYjk1MS00ZDc2LWJjYWItMzVjZmIzZTY0NDA0LTUwMDEzMDE5NS0yMDI2LTEwLTA5LWVu\/tiny\/LB-Pharmaceuticals-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Kozauer and Mr. Miller entering into employment with LB &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009031","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Kozauer and Mr. Miller entering into employment with LB &hellip; Continue reading &quot;LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-09T20:45:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-10-09T20:45:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":331,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==\",\"datePublished\":\"2026-10-09T20:45:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the \u201cinducement grant\u201d exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Kozauer and Mr. Miller entering into employment with LB &hellip; Continue reading \"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-09T20:45:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-10-09T20:45:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/"},"wordCount":331,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/","name":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==","datePublished":"2026-10-09T20:45:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI1NCM3ODg4OTU4IzUwMDEzMDE5NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-reports-inducement-grants-to-new-employee-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009031"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009031\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}